ea0041gp123 | Neuroendocrinology | ECE2016
Kutz Klaus
, Haschke Manuel
, Beglinger Christoph
, Dehning Carsten
, Cohen Fredric
Somatostatin analogues (SSAs) approved to treat acromegaly tend to suppress postprandial insulin/glucagon secretion and can worsen glucose tolerance. COR-005, a novel SSA, is under investigation for treatment of acromegaly. In rodents, COR-005 effectively inhibits GH secretion with 10,000-fold greater potency compared with insulin release suppression. We sought to determine for the first time the effects of COR-005 on postprandial glucose in humans.The p...